Oussama A. Abla

555 University Avenue
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications

Characteristics and outcome of T-cell/histiocyte-rich large B-cell lymphoma in childhood and adolescence: An international retrospective analysis.

Characteristics and outcome of T-cell/histiocyte-rich large B-cell lymphoma in childhood and adolescence: An international retrospective analysis.

Journal: British journal of haematology
Published: June 12, 2026

Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis.

Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis.

Journal: Pediatric blood & cancer
Published: April 28, 2026

Lenalidomide-Dexamethasone as an Effective and Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and Pharmacophenomic Study.

Lenalidomide-Dexamethasone as an Effective and Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and Pharmacophenomic Study.

Journal: American journal of hematology
Published: February 12, 2026

Clofarabine for relapsed/refractory LCH and non-LC histiocytosis.

Clofarabine for relapsed/refractory LCH and non-LC histiocytosis.

Journal: Blood advances
Published: February 11, 2026

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Journal: Blood advances
Published: February 11, 2026

Disease Extent, Not Lesion Location, Determines Relapse Risk in Single-System Skeletal Langerhans Cell Histiocytosis.

Disease Extent, Not Lesion Location, Determines Relapse Risk in Single-System Skeletal Langerhans Cell Histiocytosis.

Journal: Blood advances
Published: February 11, 2026

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Journal: Blood advances
Published: February 11, 2026

International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic Neoplasms.

International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic Neoplasms.

Journal: Blood
Published: January 07, 2026

Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas).

Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas).

Journal: Blood
Published: January 07, 2026

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.

Journal: Blood
Published: August 01, 2025

Value of 18F-FDG PET/CT Scans in Staging and Follow-Up of Pediatric Langerhans Cell Histiocytosis: Comparison to CT and/or MRI.

Value of 18F-FDG PET/CT Scans in Staging and Follow-Up of Pediatric Langerhans Cell Histiocytosis: Comparison to CT and/or MRI.

Journal: Children (Basel, Switzerland)
Published: July 04, 2025

Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEGasparaginase hypersensitivity.

Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEGasparaginase hypersensitivity.

Journal: Haematologica
Published: May 07, 2025
Showing 1-12 of 97

Last Updated: 09/26/2026